Dr. Richard T Maziarz is Professor of Medicine and Director of the Adult Blood & Marrow Transplantation & Immune Effector Cell Therapy Programs at Oregon Health and Science University. He is a hematologist-oncologist, skilled in blood and bone marrow transplantation, hematologic malignancies (leukemia, lymphoma, myeloma), immunology, stem cell and other cell therapies, and health economics (particularly reimbursements and costs of care). His major research interests include molecular immunology, blood and bone marrow transplantation, graft vs. host disease, and stem cells/regenerative medicine with research efforts at the basic, translational and clinical levels. Recently, he has been focused on the toxicity and efficacy of immune effector cell therapy as well as potential expanded indications for cellular therapy.

Dr. Maziarz earned his MD from Harvard Medical School. He completed his residency at University Hospitals of Cleveland, his research fellowship in Immunology at the Dana-Farber Cancer Institute, his research/clinical fellowship in Hematology at Brigham and Women’s Hospital, his research fellowship in medicine at Harvard Medical School, and his clinical fellowship in Medical Oncology at Dana-Farber Cancer Institute. He has over 300 publications, holds patents related to multipotent adult progenitor cells and their uses, and is repeatedly listed in Castle Connelly Top Doctors for Cancer. He has served as Chair of the NMDP financial working group for their system capacity initiative regarding transplantation expansion and subsequently, as Chair of the Health Economics Interest Group for ASTCT.  Among other activities, he serves on the Steering Committee of the BMT CTN, Editorial Board of Cytotherapy, Bone Marrow Transplantation, and is Associate Editor of the Journal of Transplantation & Cell Therapy and the “Current Hematologic Malignancies Reviews” for Transplantation. He is currently participating on data and safety monitoring boards related to acute myeloid leukemia, CAR T-cell therapies and acute thrombotic CVA.  He recently has been appointed to the Grants Working Group of the California Institute for Regenerative Medicine and the US Department of Health & Human Services Health Resources and Services Administration, Advisory Council on Blood Stem Cell Transplantation, wherein he is also chair of the Committee on Drug Shortages.